Department of Health and Human Services, through National Institutes of Health, awarded Capienda Biotech, LLC of San Diego, CA $1,401,698 under the SBIR program (Phase I), with work starting 2026-09-15 and running to 2028-08-31. It is one of 2 SBIR and STTR awards Capienda Biotech, LLC received in the last two years, $1,730,970 in all. Each figure links to the federal record.
The award
| Recipient | Capienda Biotech, LLC (San Diego, CA) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase I |
| Amount obligated | $1,401,698 |
| Period of performance starts | 2026-09-15 |
| Period of performance ends | 2028-08-31 |
| Award number | R44TR005335 (grant, CFDA 93.350) |
| Assistance listing | 93.350, National Center for Advancing Translational Sciences |
| Place of performance | Carlsbad, San Diego County, CA |
| Signed | 2026-09-17 |
| Recipient registry id (UEI) | EGF7MDLBABC6 |
Want the whole picture on Capienda Biotech, LLC?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Capienda Biotech, LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Capienda Biotech, LLC covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
High-throughput kinetic system for small-molecule drug discovery - abstract evidence is accumulating for higher efficacy of small molecule drugs that have off-rates slower than the pharmacokinetic clearance rate. Despite
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-09-17 | Continuation | 000 | $1,401,698 |
High-throughput kinetic system for small-molecule drug discovery - abstract evidence is accumulating for higher efficacy of small molecule drugs that have off-rates slower than the pharmacokinetic clearance rate. Despite the importance of kinetics, the standard approach is low throughput biacore testing in de novo drug discovery/screening. But we offer a new way that outruns commercial plate readers. Capienda biotech is developing the first instrument offering rapid kinetics for competitive inhibitors at high throughput for drug discovery and optimization. Advancing upon our NSF SBIR Phase I success in building a prototype instrument for highly parallel assays and sensitive detection for binding kinase targets (128 tests simultaneously), we propose the Phase II commercial instrument (up to 384 tests simultaneously) with hardware upgrade for higher-throughput kinetics. The innovative instrument design and assay chemistry enables US to characterize compounds that target human kinases for inflammatory indications and oncology. The approach is expected to be applicable across a growing portfolio of >500 kinases. Selectivity of kinase inhibitors is a major issue in targeting this class of drug targets. Drugs for auto-immune and anti-inflammatory indications have been approved by the FDA. Sixteen small molecule inhibitors target kinases regulating the immune system. Ruxolitinib, bari ...
From the federal award record.
Other SBIR and STTR awards to Capienda Biotech, LLC
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2025-08-01 | Department of Health and Human Services | SBIR Phase I | $329,272 | High-throughput kinetic system for small-molecule drug discovery - abstract evidence is ac (record) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Capienda Biotech, LLCLook up Capienda Biotech, LLC and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.